Foundation Medicine Inc (NASDAQ:FMI) COO Steven J. Kafka sold 4,405 shares of the company’s stock in a transaction dated Tuesday, April 18th. The shares were sold at an average price of $34.55, for a total transaction of $152,192.75. Following the completion of the sale, the chief operating officer now directly owns 129,038 shares in the company, valued at $4,458,262.90. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.
Steven J. Kafka also recently made the following trade(s):
- On Monday, April 3rd, Steven J. Kafka sold 2,157 shares of Foundation Medicine stock. The shares were sold at an average price of $31.96, for a total transaction of $68,937.72.
Shares of Foundation Medicine Inc (NASDAQ:FMI) remained flat at $32.30 on Friday. 85,485 shares of the stock were exchanged. Foundation Medicine Inc has a 52 week low of $15.10 and a 52 week high of $35.30. The firm’s 50-day moving average is $31.97 and its 200 day moving average is $24.02. The company’s market capitalization is $1.14 billion.
Foundation Medicine (NASDAQ:FMI) last issued its quarterly earnings data on Wednesday, February 22nd. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.96) by $0.06. The firm had revenue of $28.80 million for the quarter, compared to analysts’ expectations of $29.23 million. Foundation Medicine had a negative net margin of 84.67% and a negative return on equity of 42.21%. Foundation Medicine’s revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.55) EPS. On average, analysts forecast that Foundation Medicine Inc will post ($3.95) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Foundation Medicine Inc (FMI) COO Steven J. Kafka Sells 4,405 Shares” was published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.tickerreport.com/banking-finance/2485668/foundation-medicine-inc-fmi-coo-steven-j-kafka-sells-4405-shares.html.
A number of institutional investors have recently modified their holdings of the stock. ARK Investment Management LLC bought a new position in Foundation Medicine during the fourth quarter worth approximately $5,276,000. Chevy Chase Trust Holdings Inc. boosted its position in Foundation Medicine by 16.4% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 1,096,489 shares of the company’s stock worth $35,362,000 after buying an additional 154,168 shares in the last quarter. Peconic Partners LLC bought a new position in Foundation Medicine during the third quarter worth approximately $2,105,000. Bamco Inc. NY boosted its position in Foundation Medicine by 313.5% in the third quarter. Bamco Inc. NY now owns 103,367 shares of the company’s stock worth $2,414,000 after buying an additional 78,367 shares in the last quarter. Finally, Oppenheimer & Co. Inc. boosted its position in Foundation Medicine by 7.0% in the third quarter. Oppenheimer & Co. Inc. now owns 721,271 shares of the company’s stock worth $16,842,000 after buying an additional 47,350 shares in the last quarter. 31.44% of the stock is owned by institutional investors.
A number of brokerages have recently issued reports on FMI. Janney Montgomery Scott raised shares of Foundation Medicine from a “sell” rating to a “neutral” rating and set a $31.00 target price on the stock in a report on Tuesday, March 7th. Zacks Investment Research raised shares of Foundation Medicine from a “sell” rating to a “hold” rating in a report on Friday, March 24th. Finally, William Blair reaffirmed a “buy” rating on shares of Foundation Medicine in a report on Monday, April 3rd. Six research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $27.33.
Foundation Medicine Company Profile
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. The Company’s segment is the business of delivering molecular information about cancer to its customers. Its products provide genomic information about each patient’s individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies.
Receive News & Ratings for Foundation Medicine Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine Inc and related companies with MarketBeat.com's FREE daily email newsletter.